Previous close | 64.93 |
Open | 64.93 |
Bid | 61.50 |
Ask | 66.50 |
Strike | 37.50 |
Expiry date | 2025-01-17 |
Day's range | 64.93 - 64.93 |
Contract range | N/A |
Volume | |
Open interest | N/A |
The FDA grants priority review to Ionis' (IONS) filing seeking approval for olezarsen to treat adults with familial chylomicronemia syndrome. A final decision is expected in December 2024.
A Relative Strength Rating upgrade for Novartis ADR shows improving technical performance. Will it continue?
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.